| Market Capitalization (Millions $) |
72 |
| Shares
Outstanding (Millions) |
62 |
| Employees |
49 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-92 |
| Cash Flow (TTM) (Millions $) |
-65 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Pliant Therapeutics Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapies for fibrotic diseases. The company's primary goal is to develop drugs that target and potentially reverse fibrosis, a condition involving the formation of excess fibrous connective tissue in organs such as the liver, lungs, kidney, and heart. Pliant Therapeutics aims to provide effective treatment options for patients suffering from fibrotic diseases where there is currently no cure or limited therapeutic options available. The company's innovative approach involves identifying and targeting specific signaling pathways involved in fibrosis, with the aim to inhibit or reverse the fibrotic process. Pliant Therapeutics is committed to advancing its pipeline of potential therapeutics through rigorous research and clinical development to ultimately address the unmet medical needs of patients with fibrotic diseases.
Company Address: 331 Oyster Point Blvd. South San Francisco, 94080 CA
Company Phone Number: 481-6770 Stock Exchange / Ticker: NASDAQ PLRX
|
4.21% 